Oncolytics Biotech Appoints Steve Glover to Board and Promotes John McAdory to COO

Oncolytics Biotech Inc. appointed Steve Glover to its board of directors and promoted John McAdory to the position of Chief Operating Officer, effective June 2, 2026. These leadership changes follow the company’s ongoing efforts to restructure its executive and governance teams to support its current operational objectives.

Steve Glover joins the board of directors, bringing experience to the company’s oversight committee as it manages its clinical development programs. Concurrently, John McAdory transitions into the role of Chief Operating Officer, where he assumes responsibility for the company’s day-to-day business activities and internal operations. The company confirmed these appointments in a regulatory filing on Tuesday, noting that both individuals will immediately begin their respective duties within the organization.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI